3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Specimen Handling
122
pembrolizumab
118
Magnetic Resonance Spectroscopy
107
Carboplatin
86
Cyclophosphamide
75
Biopsy
68
Cisplatin
63
Paclitaxel
58
Bevacizumab
56
Gemcitabine
49
Nivolumab
47
fludarabine
44
Dexamethasone
39
Rituximab
38
Pemetrexed
38
Fluorouracil
37
atezolizumab
36
Docetaxel
36
Doxorubicin
34
Radiotherapy
33
Leucovorin
33
venetoclax
31
Oxaliplatin
30
Capecitabine
30
Temozolomide
28
Prednisone
28
Standard of Care
27
Radiation
27
Letrozole
27
Cetuximab
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled